Mabpharm Limited (HK:2181) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mabpharm Limited has reported a 146.4% surge in revenue for the first half of 2024, compared to the same period in 2023, despite a slight decrease in net losses and a drop in gross profit. However, the company’s net assets have seen a significant decline of 43.8%, reflecting potential challenges ahead. This performance update may attract investors’ attention due to the notable changes in financial figures.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.